We use cookies for a better user experience. Read our Privacy Policy

I Agree

Diabetes Drugs Market

Diabetes Drugs Market (Therapy - Glucagon-like Peptide-1 (GLP-1) Agonist, Dipeptidyl-peptidase-4 (DPP-4) Inhibitors, Sodium Glucose Co-transporter 2 (SGLT2) Inhibitors, and Insulin; Disease Type - Type 1 Diabetes, Type 2 Diabetes, Gestational Diabetes, Impaired Glucose Tolerance and Impaired Fasting Glycaemia; By Distribution Channel - Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025

Diabetes Drug Market: Overview

Sedentary lifestyle, overweight, and age are some of the major factors contributing to growing prevalence of diabetes cases across the globe. As per a report published by the World Health Organization (WHO), in 2014, approximately 1.9 billion people were identified as overweight wherein 600 million were categorized as obese.

Obesity and overweight are major risk factors resulting in diabetes. Increasing incidence of diabetes is explicitly fuelling demand for diabetes drugs.

Registering the demand rate, the global diabetes drugs market is anticipate to witness robust growth rate in forthcoming years.

Growing geriatric population across the world is one of the major factor fuelling demand for diabetes drugs. Elderly population is highly susceptible to certain health conditions such as blood pressure and diabetes. This, in turn, is contributing to growth of the diabetes drugs market.

Diabetes is chronic condition, where body stops production of insulin, or inhibit its absorption. As a result, blood glucose level fluctuates significantly. To regulate blood glucose level, diabetic people are supposed to be on regular diabetes medication.

As per a report published by Transparency Market Research (TMR), the diabetes drugs market is estimated to chart at a moderate CAGR of 3.6% between 2017 and 2025. At given rate, the market valuation is calculated to reach at US$58.4 bn by the end of 2025, whereas the market stood at a value of US$43.1 bn in 2016.

global-diabetes-drugs-market.jpg

Distribution Channel Enhance Visibility of Diabetes Drugs

The global diabetes drugs market is segmented on the basis of glucagon-like peptide-1 agonist, sodium glucose co-transporter 2 inhibitors, insulin, Dipeptidyl-peptidase-4 (DPP-4) inhibitors, and others. Among all, insulin holds the prominent position in the market.

Distribution channel plays a crucial role in expansion of the market and enhancing visibility of the product. Hence, diabetes drugs market is classified into retail pharmacies, hospital pharmacies, and online pharmacies. Hospital pharmacies is likely to hold prominent share in the market due to presence of trained medical staffs to sell the medicines.  Due to rising popularity of e-tail and proliferation of e-commerce, online pharmacies seems to be a promising segment for growth of the diabetes drugs market.

Type 2 Diabetes Holds Prominent Position

Diabetes is categorized into type 1 diabetes, type 2 diabetes, impaired fasting glycaemia, impaired glucose tolerance, and gestational diabetes. Among all types of diabetes, type 2 segment contribute significantly to the diabetes drugs market, due its higher prevalence across the globe. Rising cases of obesity, rising disposable income, and improving healthcare facilities are some of the key factors propelling growth of diabetes type 2 segment. Type 1 diabetes is anticipated to follow type 2 segment. Meanwhile, impaired glucose tolerance, gestational diabetes, and impaired fasting segments are estimated to rise at a moderate pace during the forecast period.

Region wise, North America market holds prominent share in the year 2016 and is likely to hold its position due to high prevalence of diabetes in the region.

Meanwhile, Europe market holds second largest share in the year 2016 due to research and development activities for drug improvisation.

Some of the top companies operating in the global diabetes drugs market are Novo Nordisk A/S, Boehringer Ingelheim GmbH, Novartis AG, Bayer AG, Merck & Co., and Sanofi. Some other prominent companies operating in this market are Takeda Pharmaceutical Company Limited, Johnson & Johnson, Boehringer Ingelheim GmbH, and Eli Lily and Company.

Type-2 Diabetes Key Focus of Players in Diabetes Drugs Market

There is a growing body of research behind antidiabetic medications as to who actually need and what type is the most effective and safe for the patient cohort. A key driver for the diabetes drugs market is the high risks the disease brings to the patient, particularly in patients with type-2 diabetes. Extensive research has been made by drugmakers to develop formulations that can help lower the cardiovascular risks in patient populations, thereby expanding the growth potential in the diabetes drugs market. Some of the popular antidiabetic drugs are metformin, sulfonylureas, dipeptidyl peptidase-4 inhibitors, glitazones, SGLT2 inhibitors, and glinides. However, not every patient with type-2 diabetes may need medication. The decision to continue with certain medications should be based on sound clinical decision, wherein physicians’ recommendations occupy critical position. Over the past few years, incretin mimetics has also gained some attention among industry players operating in the diabetes drugs market. However, the verdict is still out of its long-term advantages. The worldwide prevalence of diabetes will continue to propel drugmakers to enrich their drug pipeline to meet the unmet need in patient populations. They are relentlessly aiming at reducing the side effects and increase the safety profiles. The recent approval of pharmacological agents is a key developmental trend that will spur growth in the market.

The current Covid-19 pandemic has reiterated the criticality of managing chronic diseases and their role in public health. Diabetics are one of the cohorts that have at the forefront of high risk factors for being infected badly with the virus. Thus, the population healthcare systems are emphasizing on consolidating the infrastructure to improve care for chronic diseases, including diabetes and cardiovascular diseases. This also has changed the current course of development for drug makers to an extent, encouraging research and development investments in the diabetes drugs market. Also, the growing awareness among the general populace will help in patients make more clinically-informed decisions on the pharmacological therapies they need.

Diabetes Drugs Market has been segmented as given below:

by Therapy

  • Glucagon-like peptide-1 (GLP-1) agonist
  • Dipeptidyl-peptidase-4 (DPP-4) inhibitors
  • Sodium glucose co-transporter 2 (SGLT2) inhibitors
  • Insulin
  • Others

by Disease Type

  • Type 1 Diabetes
  • Type 2 Diabetes
  • Gestational Diabetes
  • Impaired Glucose Tolerance and Impaired Fasting Glycaemia

by Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

by Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • Italy
    • Spain
    • UK
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia & New Zealand
    • Rest of Asia Pacific
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America

Interested in this report?
Get a FREE sample now!

Get Free Sample

*Get Sample Report (PDF) sent to your email within minutes

1. Preface
     1.1. Market Segmentation
     1.2. Key Research Objectives
     1.3. Research Highlights

2. Assumptions and Research Methodology
     2.1. Secondary Research Methodology
     2.2. Primary Research Methodology
     2.3. Analysis Research Methodology
     2.4. Final Report & Conclusions Research Methodology

3. Executive Summary: Global Diabetes Drugs Market

4. Market Overview
     4.1. Introduction
            4.1.1. Therapy Definition
            4.1.2. Industry Evolution / Developments
     4.2. Overview
     4.3. Key Market Indicators
            4.3.1. Region/Country Specific
            4.3.2. Product/Application/Technology Specific
            4.3.3. Target Market Specific – Global Scenario
     4.4. Market Dynamics
            4.4.1. Drivers
            4.4.2. Restraints
            4.4.3. Opportunity
            4.4.3. Opportunity Analysis
            4.4.4. Trends
     4.5. Global Diabetes Drugs Market Analysis and Forecasts, 2015–2025
     4.6. Porter’s Five Forces Analysis 
     4.7. Value Chain Analysis 
     4.8. Pipeline Analysis 

5. Global Diabetes Drugs Market Analysis and Forecasts, By Therapy 
     5.1. Introduction & Definition
     5.2. Key Findings / Developments
     5.3. Key Trends
     5.4. Market Value Forecast by Therapy, 2015–2025
            5.4.1. Glucagon-like peptide-1 (GLP-1) agonist
            5.4.2. Dipeptidyl-peptidase-4 (DPP-4) inhibitors
            5.4.3. Sodium glucose co-transporter 2 (SGLT2) inhibitors
            5.4.4. Insulin
            5.4.5. Others
     5.5. Market Attractiveness by Therapy 

6. Global Diabetes Drugs Market Analysis and Forecasts, By Disease Type 
     6.1. Introduction & Definition
     6.2. Key Findings / Developments
     6.3. Key Trends
     6.4. Market Value Forecast by Disease Type, 2015–2025
            6.4.1. Type 1 Diabetes
            6.4.2. Type 2 Diabetes
            6.4.3. Gestational Diabetes
            6.4.4. Impaired Glucose Tolerance and Impaired Fasting Glycaemia
     6.5. Disease Type Comparison Matrix
     6.6. Market Attractiveness by Disease Type 

7. Global Diabetes Drugs Market Analysis and Forecasts, By Distribution Channel 
     7.1. Introduction & Definition
     7.2. Key Findings / Developments
     7.3. Key Trends
     7.4. Market Value Forecast by Distribution Channel, 2015–2025
            7.4.1. Hospital Pharmacies
            7.4.2. Retail Pharmacies
            7.4.3. Online Pharmacies
     7.5. Distribution Channel Comparison Matrix
     7.6. Market Attractiveness by Distribution Channel 

8. Global Diabetes Drugs Market Analysis and Forecasts, By Region
     8.1. Key Findings
     8.2. Policies and Regulations
     8.3. Market Value Forecast by Region
            8.3.1. North America 
            8.3.2. Europe 
            8.3.3. Asia Pacific 
            8.3.4. Middle East & Africa 
            8.3.5. Latin America 
     8.4. Market Attractiveness by Country/Region

9. North America Diabetes Drugs Market Analysis and Forecast
     9.1. Introduction
            9.1.1. Key Findings
            9.1.2. Policies and Regulations
            9.1.3. Price Trend Analysis
            9.1.4. Key Trends
     9.2. Market Value Forecast by Therapy, 2015–2025
            9.2.1. Glucagon-like peptide-1 (GLP-1) agonist
            9.2.2. Dipeptidyl-peptidase-4 (DPP-4) inhibitors
            9.2.3. Sodium glucose co-transporter 2 (SGLT2) inhibitors
            9.2.4. Insulin
            9.2.5. Others
     9.3. Market Value Forecast by Disease Type, 2015–2025
            9.3.1. Type 1 Diabetes
            9.3.2. Type 2 Diabetes
            9.3.3. Gestational Diabetes
            9.3.4. Impaired Glucose Tolerance and Impaired Fasting Glycaemia
     9.4. Market Value Forecast by Distribution Channel, 2015–2025
            9.4.1. Hospital Pharmacies
            9.4.2. Retail Pharmacies
            9.4.3. Online Pharmacies
     9.5. Market Value Forecast by Country, 2015–2025
            9.5.1. U. S. 
            9.5.2. Canada
     9.6. Market Attractiveness Analysis 
            9.6.1. by Therapy 
            9.6.2. by Disease Type 
            9.6.3. by Distribution Channel 
            9.6.4. by Country
     9.7. Key Trends

10. Europe Diabetes Drugs Market Analysis and Forecast
     10.1. Introduction
            10.1.1. Key Findings
            10.1.2. Policies and Regulations
            10.1.3. Price Trend Analysis
            10.1.4. Key Trends
     10.2. Market Value Forecast by Therapy, 2015–2025
            10.2.1. Glucagon-like peptide-1 (GLP-1) agonist
            10.2.2. Dipeptidyl-peptidase-4 (DPP-4) inhibitors
            10.2.3. Sodium glucose co-transporter 2 (SGLT2) inhibitors
            10.2.4. Insulin
            10.2.5. Others
     10.3. Market Value Forecast by Disease Type, 2015–2025
            10.3.1. Type 1 Diabetes
            10.3.2. Type 2 Diabetes
            10.3.3. Gestational Diabetes
            10.3.4. Impaired Glucose Tolerance and Impaired Fasting Glycaemia
     10.4. Market Value Forecast by Distribution Channel, 2015–2025
            10.4.1. Hospital Pharmacies
            10.4.2. Retail Pharmacies
            10.4.3. Online Pharmacies
     10.5. Market Value Forecast by Country, 2015–2025
            10.5.1. Germany 
            10.5.2. France
            10.5.3. Italy 
            10.5.4. Spain 
            10.5.5. UK
            10.5.6. Rest of Europe
     10.6. Market Attractiveness Analysis 
            10.6.1. by Therapy 
            10.6.2. by Disease Type 
            10.6.3. by Distribution Channel 
            10.6.4. by Country
     10.7. Key Trends

11. Asia Pacific Diabetes Drugs Market Analysis and Forecast
     11.1. Introduction
            11.1.1. Key Findings
            11.1.2. Policies and Regulations
            11.1.3. Price Trend Analysis
            11.1.4. Key Trends
     11.2. Market Value Forecast by Therapy, 2015–2025
            11.2.1. Glucagon-like peptide-1 (GLP-1) agonist
            11.2.2. Dipeptidyl-peptidase-4 (DPP-4) inhibitors
            11.2.3. Sodium glucose co-transporter 2 (SGLT2) inhibitors
            11.2.4. Insulin
            11.2.5. Others
     11.3. Market Value Forecast by Disease Type, 2015–2025
            11.3.1. Type 1 Diabetes
            11.3.2. Type 2 Diabetes
            11.3.3. Gestational Diabetes
            11.3.4. Impaired Glucose Tolerance and Impaired Fasting Glycaemia
     11.4. Market Value Forecast by Distribution Channel, 2015–2025
            11.4.1. Hospital Pharmacies
            11.4.2. Retail Pharmacies
            11.4.3. Online Pharmacies
     11.5. Market Value Forecast by Country, 2015–2025
            11.5.1. China
            11.5.2. Japan
            11.5.3. India
            11.5.4. Australia & New Zealand
            11.5.5. Rest of Asia Pacific
     11.6. Market Attractiveness Analysis 
            11.6.1. by Therapy 
            11.6.2. by Disease Type 
            11.6.3. by Distribution Channel 
            11.6.4. by Country
     11.7 Key Trends

12. Middle East & Africa Diabetes Drugs Market Analysis and Forecast
     12.1. Introduction
            12.1.1. Key Findings
            12.1.2. Policies and Regulations
            12.1.3. Price Trend Analysis
            12.1.4. Key Trends
     12.2. Market Value Forecast by Therapy, 2015–2025
            12.2.1. Glucagon-like peptide-1 (GLP-1) agonist
            12.2.2. Dipeptidyl-peptidase-4 (DPP-4) inhibitors
            12.2.3. Sodium glucose co-transporter 2 (SGLT2) inhibitors
            12.2.4. Insulin
            12.2.5. Others
     12.3. Market Value Forecast by Disease Type, 2015–2025
            12.3.1. Type 1 Diabetes
            12.3.2. Type 2 Diabetes
            12.3.3. Gestational Diabetes
            12.3.4. Impaired Glucose Tolerance and Impaired Fasting Glycaemia
     12.4. Market Value Forecast by Distribution Channel, 2015–2025
            12.4.1. Hospital Pharmacies
            12.4.2. Retail Pharmacies
            12.4.3. Online Pharmacies
     12.5. Market Value Forecast by Country, 2015–2025
            12.5.1. GCC Countries
            12.5.2. South Africa
            12.5.3. Rest of Middle East & Africa
     12.6. Market Attractiveness Analysis 
            12.6.1. by Therapy 
            12.6.2. by Disease Type 
            12.6.3. by Distribution Channel 
            12.6.4. by Country
     12.7. Key Trends

13. Latin America Diabetes Drugs Market Analysis and Forecast
     13.1. Introduction
            13.1.1. Key Findings
            13.1.2. Policies and Regulations
            13.1.3. Price Trend Analysis
            13.1.4. Key Trends
     13.2. Market Value Forecast by Therapy, 2015–2025
            13.2.1. Glucagon-like peptide-1 (GLP-1) agonist
            13.2.2. Dipeptidyl-peptidase-4 (DPP-4) inhibitors
            13.2.3. Sodium glucose co-transporter 2 (SGLT2) inhibitors
            13.2.4. Insulin
            13.2.5. Others
     13.3. Market Value Forecast by Disease Type, 2015–2025
            13.3.1. Type 1 Diabetes
            13.3.2. Type 2 Diabetes
            13.3.3. Gestational Diabetes
            13.3.4. Impaired Glucose Tolerance and Impaired Fasting Glycaemia
     13.4. Market Value Forecast by Distribution Channel, 2015–2025
            13.4.1. Hospital Pharmacies
            13.4.2. Retail Pharmacies
            13.4.3. Online Pharmacies
     13.5. Market Value Forecast by Country, 2015–2025
            13.5.1. Brazil
            13.5.2. Mexico
            13.5.3. Rest of Latin America
     13.6. Market Attractiveness Analysis 
            13.6.1. by Therapy 
            13.6.2. by Disease Type 
            13.6.3. by Distribution Channel 
            13.6.4. by Country
     13.7. Key Trends

14. Competition Landscape
     14.1. Competition Matrix
     14.2. Market Share Analysis by Company (2015)
     14.3. Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)
            14.3.1. Novo Nordisk A/S
                      14.3.1.1. Company Description
                      14.3.1.2. Financial Overview
                      14.3.1.3. Strategic Overview
                      14.3.1.4. Recent Developments
                      14.3.1.5. SWOT ANALYSIS
            14.3.2. Sanofi
                      14.3.2.1. Company Description
                      14.3.2.2. Financial Overview
                      14.3.2.3. Strategic Overview
                      14.3.2.4. Recent Developments
                      14.3.2.5. SWOT ANALYSIS
            14.3.3. Merck & Co., Inc. 
                      14.3.3.1. Company Description
                      14.3.3.2. Financial Overview
                      14.3.3.3. Strategic Overview
                      14.3.3.4. Recent Developments
                      14.3.3.5. SWOT ANALYSIS
            14.3.4. Eli Lilly and company
                      14.3.4.1. Company Description
                      14.3.4.2. Financial Overview
                      14.3.4.3. Strategic Overview
                      14.3.4.4. Recent Developments
                      14.3.4.5. SWOT ANALYSIS
            14.3.5. AstraZeneca
                      14.3.5.1. Company Description
                      14.3.5.2. Financial Overview
                      14.3.5.3. Strategic Overview
                      14.3.5.4. Recent Developments
                      14.3.5.5. SWOT ANALYSIS
            14.3.6. Boehringer Ingelheim GmbH
                      14.3.6.1. Company Description
                      14.3.6.2. Financial Overview
                      14.3.6.3. Strategic Overview
                      14.3.6.4. Recent Developments
                      14.3.6.5. SWOT ANALYSIS
            14.3.7. Johnson & Johnson
                      14.3.7.1. Company Description
                      14.3.7.2. Financial Overview
                      14.3.7.3. Strategic Overview
                      14.3.7.4. Recent Developments
                      14.3.7.5. SWOT ANALYSIS
            14.3.8. Novartis AG
                      14.3.8.1. Company Description
                      14.3.8.2. Financial Overview
                      14.3.8.3. Strategic Overview
                      14.3.8.4. Recent Developments
                      14.3.8.5. SWOT ANALYSIS
            14.3.9. Takeda Pharmaceutical Company Limited
                      14.3.9.1. Company Description
                      14.3.9.2. Financial Overview
                      14.3.9.3. Strategic Overview
                      14.3.9.4. Recent Developments
                      14.3.9.5. SWOT ANALYSIS
            14.3.10. Bayer AG
                      14.3.10.1. Company Description
                      14.3.10.2. Financial Overview
                      14.3.10.3. Recent Developments
                      14.3.10.4. SWOT ANALYSIS

List of Tables

Table 1: Opportunity Map, 2016
Table 2: Opportunity Map, 2016
Table 3: Opportunity Map, 2016
Table 4: Pipeline Analysis, By Phase 3 Drugs
Table 5: Pipeline Analysis, By Phase 2 (1/2)
Table 6: Pipeline Analysis, by phase 2 (2/2)
Table 7: Global Diabetes Drugs Market Size (US$ Mn) Forecast, by Therapy, 2015–2025
Table 8: Global Diabetes Drugs Market Size (US$ Mn) Forecast, by Disease Type, 2015–2025
Table 9: Global Diabetes Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 10: Global Diabetes Drugs Market Size (US$ Mn) Forecast, by Region, 2015–2025
Table 11: North America Diabetes Drugs Market Value (US$ Mn) Forecast, by Therapy, 2015–2025
Table 12: North America Diabetes Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2015–2025
Table 13: North America Diabetes Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 14: North America Diabetes Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
Table 15: Europe Diabetes Drugs Market Value (US$ Mn) Forecast, by Therapy, 2015–2025
Table 16: Europe Diabetes Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2015–2025
Table 17: Europe Diabetes Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 18: Europe Diabetes Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
Table 19: Asia Pacific Diabetes Drugs Market Value (US$ Mn) Forecast, by Therapy, 2015–2025
Table 20: Asia Pacific Diabetes Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2015–2025
Table 21: Asia Pacific Diabetes Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 22: Asia Pacific Diabetes Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
Table 23: Middle East & Africa Diabetes Drugs Market Value (US$ Mn) Forecast, by Therapy,
Table 24: Middle East & Africa Diabetes Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2015–2025
Table 25: Middle East & Africa Diabetes Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 26: Middle East & Africa Diabetes Drugs Market Value (US$ Mn) Forecast, by Country, 2015–2025
Table 27: Latin America Diabetes Drugs Market Value (US$ Mn) Forecast, by Therapy, 2015–2025
Table 28: Latin America Diabetes Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2015–2025
Table 29: Latin America Diabetes Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 30: Latin America Diabetes Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2015–2025

List of Figures

Figure 01: Diabetes Drugs Market, by Therapy, Market Size (US$ Mn), 2016 (A)
Figure 02: Diabetes Drugs Market Revenue (%), by Disease Type, 2016 (A)
Figure 03: Global Diabetes Drugs Market Size (US$ Mn) Forecast, 2015–2025
Figure 04: Global Diabetes Drugs Market Value Share, by Therapy (2016)
Figure 05: Global Diabetes Drugs Market Value Share, by Disease Type (2016)
Figure 06: Global Diabetes Drugs Market Value Share, by Distribution Channel (2016)
Figure 07: Global Diabetes Drugs Market Value Share, by Therapy, 2016 and 2025
Figure 08: Global Diabetes Drugs Market Attractiveness, by Therapy, 2017–2025
Figure 09: Global Diabetes Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by GLP-1, 2015–2025
Figure 10: Global Diabetes Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by DPP-4, 2015–2025
Figure 11: Global Diabetes Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by SGLT-2, 2015–2025
Figure 12: Global Diabetes Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Insulin, 2015–2025
Figure 13: Global Diabetes Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2015–2025
Figure 14: Global Diabetes Drugs Market Value Share, by Disease Type, 2016 and 2025
Figure 15: Global Diabetes Drugs Market Attractiveness, by Disease Type, 2017–2025
Figure 16: Global Diabetes Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Type 1 Diabetes, 2015–2025
Figure 17: Global Diabetes Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Type 2 Diabetes, 2015–2025
Figure 18: Global Diabetes Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Gestational Diabetes, 2015–2025
Figure 19: Global Diabetes Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Impaired Glucose Tolerance and Impaired Fasting Glycaemia, 2015–2025
Figure 20: Global Diabetes Drugs Market Value Share, by Distribution Channel, 2016 and 2025
Figure 21: Global Diabetes Drugs Market Attractiveness, by Distribution Channel, 2017–2025
Figure 22: Global Diabetes Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hospital Pharmacies, 2015–2025
Figure 23: Global Diabetes Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Retail Pharmacies, 2015–2025
Figure 24: Global Diabetes Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Online Pharmacies, 2015–2025
Figure 25: Global Diabetes Drugs Market Value Share, by Region, 2017 and 2025 
Figure 26: Global Diabetes Drugs Market Attractiveness, by Region, 2017–2025
Figure 27: North America Diabetes Drugs Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2025
Figure 28: North America Diabetes Drugs Market Value Share Analysis, by Therapy, 2016 and 2025
Figure 29: North America Diabetes Drugs Market Value Share Analysis, by Disease Type, 2016 and 2025
Figure 30: North America Diabetes Drugs Market Value Share Analysis, by Distribution Channel, 2016 and 2025
Figure 31: North America Diabetes Drugs Market Value Share Analysis, by Country/Sub-region, 2016 and 2025
Figure 32: North America Diabetes Drugs Market Attractiveness Analysis, by Therapy
Figure 33: North America Diabetes Drugs Market Attractiveness Analysis, by Disease Type
Figure 34: North America Diabetes Drugs Market Attractiveness Analysis, by Distribution Channel 
Figure 35: North America Diabetes Drugs Market Attractiveness Analysis, by Country
Figure 36: Europe Diabetes Drugs Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2025
Figure 37: Europe Diabetes Drugs Market Value Share Analysis, by Therapy, 2016 and 2025
Figure 38: Europe Diabetes Drugs Market Value Share Analysis, by Disease Type, 2016 and 2025
Figure 39: Europe Diabetes Drugs Market Value Share Analysis, by Distribution Channel, 2016 and 2025
Figure 40: Europe Diabetes Drugs Market Value Share Analysis, by Country/Sub-region, 2016 and 2025
Figure 41: Europe Diabetes Drugs Market Attractiveness Analysis, by Therapy
Figure 42: Europe Diabetes Drugs Market Attractiveness Analysis, by Disease Type
Figure 43: Europe Diabetes Drugs Market Attractiveness Analysis, by Distribution Channel 
Figure 44: Europe Diabetes Drugs Market Attractiveness Analysis, by Country/Sub-region
Figure 45: Asia Pacific Diabetes Drugs Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2025
Figure 46: Asia Pacific Diabetes Drugs Market Value Share Analysis, by Therapy, 2016 and 2025
Figure 47: Asia Pacific Diabetes Drugs Market Value Share Analysis, by Disease Type, 2016 and 2025
Figure 48: Asia Pacific Diabetes Drugs Market Value Share Analysis, by Distribution Channel, 2016 and 2025
Figure 49: Asia Pacific Diabetes Drugs Market Value Share Analysis, by Country/Sub-region, 2016 and 2025
Figure 50: Asia Pacific Diabetes Drugs Market Attractiveness Analysis, by Therapy
Figure 51: Asia Pacific Diabetes Drugs Market Attractiveness Analysis, by Disease Type
Figure 52: Asia Pacific Diabetes Drugs Market Attractiveness Analysis, by Distribution Channel 
Figure 53: Asia Pacific Diabetes Drugs Market Attractiveness Analysis, by Country
Figure 54: Middle East & Africa Diabetes Drugs Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2025
Figure 55: Middle East & Africa Diabetes Drugs Market Value Share Analysis, by Therapy, 2016 and 2025
Figure 56: Middle East & Africa Diabetes Drugs Market Value Share Analysis, by Disease Type, 2016 and 2025
Figure 57: Middle East & Africa Diabetes Drugs Market Value Share Analysis, by Distribution Channel, 2016 and 2025
Figure 58: Middle East & Africa Diabetes Drugs Market Value Share Analysis, by Country/Sub-region, 2016 and 2025
Figure 59: Middle East & Africa Diabetes Drugs Market Attractiveness Analysis, by Therapy
Figure 60: Middle East & Africa Diabetes Drugs Market Attractiveness Analysis, by Disease Type
Figure 61: Middle East & Africa Diabetes Drugs Market Attractiveness Analysis, by Distribution Channel 
Figure 62: Middle East & Africa Market Attractiveness Analysis, by Country/Sub-region
Figure 63: Latin America Diabetes Drugs Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2025
Figure 64: Latin America Diabetes Drugs Market Value Share Analysis, by Therapy, 2016 and 2025
Figure 65: Latin America Diabetes Drugs Market Value Share Analysis, by Disease Type, 2016 and 2025
Figure 66: Latin America Diabetes Drugs Market Value Share Analysis, by Distribution Channel, 2016 and 2025
Figure 67: Latin America Diabetes Drugs Market Value Share Analysis, by Country/Sub-region, 2016 and 2025
Figure 68: Latin America Diabetes Drugs Market Attractiveness Analysis, by Therapy
Figure 69: Latin America Diabetes Drugs Market Attractiveness Analysis, by Disease Type
Figure 70: Latin America Diabetes Drugs Market Attractiveness Analysis, by Distribution Channel 
Figure 71: Latin America Market Attractiveness Analysis, by Country/Sub-region
Figure 72: Global Diabetes Drugs Market Share, by Company, 2016

Transparency Market Research Plus

Get a free copy if the report you purchased is updated within 90 days

Copyright © Transparency Market Research, Inc. All Rights reserved